Developing Restorative Treatments for Pain, Hearing Loss, and Sensory Neuron Disorders

Our Company

Hoba Therapeutics was established in 2017 with seed funding from Novo Holdings and Borean Innovation.

Our mission is to develop novel biopharmaceuticals for the relief, prevention, and treatment of chronic pain and hearing loss

Neuropathic Pain and Hearing Loss


Our compounds are first-in-class therapeutic proteins for the treatment of chronic pain and hearing loss.

HB-086 and HB-097 are recombinant drug candidates of human Meteorin and human Cometin. This family of proteins have unique therapeutic properties and act on sensory nerve cells and their supporting glia cells.

Our Pipeline

HB-086 is in late preclinical development for Neuropathic Pain. Target indications are Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia.

HB-097 is in preclinical development for sensorineural hearing loss. The target indication is Ototix Hearing Loss.

Latest News

14 October 2021

Hoba Therapeutics has been selected by The European Commission’s European Innovation Council (EIC) as a start-up champion. Hoba will receive grant funding and qualifies for further equity investment from EIC Accelerator.

August 2019 - New Publication

Antihyperalgesic effects of Meteorin in the rat chronic constriction injury model: a replication study.

October 2018 - Grand Solution Funding  (IFD)

Danish Hoba Therapeutics and a consortium of national and international partners have secured the ongoing development of the drug candidate HB-086 for treatment of neuropathic pain with an investment from Innovation Fund Denmark (IFD) of DKK18.4M (≈€2.5M), and thereby a major step towards clinical trials